JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models

Min Sil Kang(CHA University), Yong Wha Moon(CHA University Bundang Medical Center)

British Journal of Cancer

May 6, 2026

10.1038/s41416-026-03411-3

Cited by 0

Related Papers

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma

|Oncotarget|2014|34

SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer

|Cell Death and Disease|2025|4

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.

|PubMed Central|2015|1